Jeffrey M. Leiden - 13 Apr 2022 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
Executive Chairman, Director
Signature
/s/ Sabrina Yohai, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
13 Apr 2022
Net transactions value
-$4,563,653
Form type
4
Filing time
14 Apr 2022, 16:35:09 UTC
Previous filing
28 Feb 2022
Next filing
27 Jul 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Sale $4,563,653 -15,789 -18% $289.04 74,160 13 Apr 2022 Direct F1, F2, F3
holding VRTX Common Stock 440 13 Apr 2022 401(k)
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1.
F2 Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3 Open market sales reported on this line occurred at a weighted average price of $289.04 (range $289.00 to $289.58).